Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to market the combination of Akoya’s spatial biology solutions, including its PhenoImager® systems and PhenoCode™ reagents with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples.

The agreement facilitates a streamlined workflow for whole-slide, multiomic imaging, where protein and RNA biomarkers play complementary roles in defining cell phenotypes and cell states, respectively, in a tissue sample. Measuring both protein and RNA analytes provides researchers with a more comprehensive understanding of tumor progression, molecules and biologics, enabling development of more accurate biomarker signatures.

The Thermo Fisher ViewRNA assays are compatible with Akoya’s PhenoCode™ protein panels, which deliver industry-leading solutions for high-plex and high-throughput spatial proteomics. The aim is to offer a comprehensive suite of ready-to-use and customizable multiomic solutions, streamlining the progression of biomarker programs from discovery to diagnostics.

“We are excited to work with Thermo Fisher to combine their RNA solutions with our platforms to offer a leading multiomic solution for researchers to further advance the spatial biology field,” said Brian McKelligon, CEO, Akoya Biosciences.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential of our products and services and other matters regarding our business strategies and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com. 

Akoya Biosciences Investor Contact:

Priyam Shah
Sr. Director, Investor Relations
investors@akoyabio.com

Akoya Biosciences Media Contact:

Christine Quern
media@akoyabio.com